B-other ALL classification by Targeted RNA-sequencing

We present a comprehensive genetic study of 144 pediatric B-other Acute Lymphoblastic Leukemia cases diagnosed and treated at Boldrini Children's Hospital (Brazil). We performed a targeted RNA-sequencing to evaluated the benefits of introducing genomic technologies into routine diagnostics. Targeted RNA-sequencing further classified 66.7% B-other cases. All 'classical' and novel ALL subgroups, except for iAMP21, hyper- and hypodiploid cases were identified. In addition, clinically important genetic alterations as druggable lesions and prognostic factors were found. Here, we uploaded files that contain: 1. Gene expression data from the entire cohort studied, n=184 (Log2+1 TPM normalized gene expression data). Tab-delimited file (.csv) that contains a row for gene, a column for each sample, and expression values for each gene in each sample. Annotation labels are in the first three rows and in the first column. 2. A subset of 23 BAM (Binary Alignment/Map) files for representative ALL cases, including BCR-ABL1, ETV6-RUNX1, TCF3-PBX1, KMT2A-r, High-Hyperdiploidy; DUX4-r, iAMP21, PAX5-driven, ABL-class fusion, JAK2-fusion, EPOR-fusion, CRLF2-high, ZNF384-r, MEF2D-r, NUTM1-r, B-'rest', IKZF1del, and ERGdel. 3- Genetic information of the 23 BAM files provided (tab-delimited file, .txt).